Dominican Republic

Reimbursed Care Access

The Dominican Republic regulates psychoactive drugs under Law No. 50-88 and its implementing regulation (Decreto 288-96), and the national drug-control architecture emphasizes criminal control and public-health enforcement over expanded medical use of classical psychedelics. Ketamine is used within conventional medical practice as an anaesthetic (consistent with WHO essential-medicines guidance), but there is no documented national reimbursement program or formal regulatory pathway in the public health system for psychedelic-assisted psychiatric treatments (e.g., psilocybin- or MDMA-assisted therapy) outside of authorized research or standard medical uses of approved anesthetics. Most classical psychedelic compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, ibogaine, 2C‑X, etc.) are controlled under the national narcotics law and are not authorised for routine medical treatment outside approved clinical research or explicit regulatory exemptions.